Sangamo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	39.55	57.8	176.23	111.3	110.7
Revenue Growth (YoY)	-31.57%	-67.20%	58.34%	0.54%	-6.34%
Cost of Revenue	112.67	111.32	230.46	249.9	230.82
Gross Profit	-73.12	-53.52	-54.23	-138.6	-120.12
Selling, General & Admin	34.89	44.73	60.07	62.68	63.22
Operating Expenses	34.89	44.73	60.07	62.68	63.22
Operating Income	-108	-98.25	-114.29	-201.28	-183.34
Interest & Investment Income	1.3	1.51	8.25	6.43	5.35
Currency Exchange Gain (Loss)	-3.7	1.6	2.85	-	-
Other Non Operating Income (Expenses)	0.14	2.75	-	-	-
EBT Excluding Unusual Items	-110.27	-92.39	-103.19	-194.85	-177.99
Merger & Restructuring Charges	-	-0.2	-4.7	-	-
Impairment of Goodwill	-	-	-38.14	-	-
Asset Writedown	-13.24	-5.52	-116.88	-	-
Other Unusual Items	-	-	-	3	-
Pretax Income	-123.5	-98.11	-262.9	-191.85	-177.99
Income Tax Expense	-0.57	-0.17	-5.07	0.43	0.31
Earnings From Continuing Operations	-122.93	-97.94	-257.83	-192.28	-178.3
Minority Interest in Earnings	-	-	-	-	0.01
Net Income	-122.93	-97.94	-257.83	-192.28	-178.29
Net Income to Common	-122.93	-97.94	-257.83	-192.28	-178.29
Shares Outstanding (Basic)	280	202	174	154	145
Shares Outstanding (Diluted)	280	202	174	154	145
Shares Change (YoY)	38.92%	15.62%	13.02%	6.76%	7.53%
EPS (Basic)	-0.44	-0.49	-1.48	-1.25	-1.23
EPS (Diluted)	-0.44	-0.49	-1.48	-1.25	-1.23
Free Cash Flow	-97.31	-67.41	-246	-243.8	-256.53
Free Cash Flow Per Share	-0.35	-0.33	-1.41	-1.58	-1.77
Gross Margin	-184.86%	-92.60%	-30.77%	-124.53%	-108.51%
Operating Margin	-273.07%	-169.98%	-64.85%	-180.85%	-165.62%
Profit Margin	-310.81%	-169.45%	-146.30%	-172.76%	-161.05%
Free Cash Flow Margin	-246.03%	-116.62%	-139.59%	-219.05%	-231.73%
EBITDA	-104.04	-93.14	-99.23	-189.17	-173.9
EBITDA Margin	-263.05%	-161.14%	-56.31%	-169.97%	-157.09%
D&A For EBITDA	3.96	5.11	15.07	12.11	9.44
EBIT	-108	-98.25	-114.29	-201.28	-183.34
EBIT Margin	-273.07%	-169.98%	-64.85%	-180.85%	-165.61%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.